Cancer Drug Prices Skyrocket Past $480,000 Annually

Revolution Medicines has launched Rasonque, a new pancreatic cancer treatment with an annual price tag of roughly $480,000. This exceptionally high cost underscores a significant inflation in cancer drug pricing seen over the last twenty years.

This price point is becoming routine for cutting-edge cancer therapies, with some CAR-T treatments costing $600,000 for a single infusion. While Rasonque has demonstrated clinical benefits, prolonging life expectancy for pancreatic cancer patients, its cost raises concerns about accessibility.

Experts acknowledge Rasonque's substantial clinical advantages over existing treatments, a factor not always present with high-priced cancer drugs. However, the escalating costs are borne by government programs, employers, and patients, prompting debate on fair pricing and market limits.

Revolution Medicines reports significant investments in research and development, with $3.3 billion spent this decade. The company offers financial assistance programs for uninsured or underinsured patients, aiming to mitigate out-of-pocket expenses.

Pharmacy benefit managers are reviewing Rasonque, with initial assessments suggesting it may be covered by most insurance plans due to its efficacy and lack of alternatives. However, coverage limitations and prior authorization requirements could still restrict patient access.

The Inflation Reduction Act's out-of-pocket cap for Medicare patients offers some protection, limiting annual drug costs to $2,400. Without this cap, patients could face over $25,000 annually for Rasonque.